CoLucid Pharmaceuticals (CLCD) Receives Media Impact Score of 0.30

Media headlines about CoLucid Pharmaceuticals (NASDAQ:CLCD) have trended positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. CoLucid Pharmaceuticals earned a media sentiment score of 0.30 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 43.6568126847622 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:

ILLEGAL ACTIVITY WARNING: “CoLucid Pharmaceuticals (CLCD) Receives Media Impact Score of 0.30” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://ledgergazette.com/2017/10/10/colucid-pharmaceuticals-clcd-receives-media-impact-score-of-0-30.html.

About CoLucid Pharmaceuticals

CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.

Insider Buying and Selling by Quarter for CoLucid Pharmaceuticals (NASDAQ:CLCD)

Receive News & Ratings for CoLucid Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply